Table 3.
Univariable prognostic factor analysis for overall survival (OS), progression/relapse free survival (PFS), non-relaplse/progression related mortality (NRM) and relapse/progression incidence (RI) with estimates of probabilities/cumulative incidences (95% confidence intervals) at 4 years after salvage auto-HCT.
| OS | PFS | NRM | RI | ||||||
|---|---|---|---|---|---|---|---|---|---|
| P | P | P | P | ||||||
| Age | 0.17 | 0.06 | 0.20 | 0.55 | |||||
| <60 years | 49% (40–57%) | 13% (7–19%) | 11% (6–16%) | 77% (70–84%) | |||||
| ≥60 years | 55% (45–65%) | 19% (11–27%) | 6% (1–11%) | 75% (66–83%) | |||||
| Sex | 0.83 | 0.07 | 0.005 | 0.02 | |||||
| Male | 52% (44–60%) | 14% (9–20%) | 6% (2–10%) | 80% (73–86%) | |||||
| Female | 51% (40–62%) | 18% (9–27%) | 14% (6–22%) | 68% (57–79%) | |||||
| Year of salvage auto-HCT | <0.001 | 0.02 | 0.20 | 0.41 | |||||
| 2000–2004 | 36% (27–46%) | 8% (3–14%) | 13% (6–19%) | 79% (71–87%) | |||||
| 2005–2009 | 61% (42–80%) | 14% (1–27%) | 4% (0–10%) | 82% (68–96%) | |||||
| 2010–2014 | 63% (52–74%) | 25% (15–36%) | 4% (0–8%) | 71% (60–81%) | |||||
| 2015–2018 | 66% (48–83%) | 13% (0–27%) | 14% (1–27%) | 73% (57–90%) | |||||
| Number of previous auto-HCTs | 0.98 | 0.86 | 0.94 | 0.85 | |||||
| 1 | 52% (45–59%) | 16% (11–21%) | 9% (5–12%) | 76% (69–82%) | |||||
| 2 | 49% (34–65%) | 14% (3–24%) | 10% (1–19%) | 77% (64–90%) | |||||
| Time to relapse after the previous auto-HCT | <0.001 | <0.001 | 0.24 | 0.02 | |||||
| <30 months | 35% (26–45%) | 10% (3–16%) | 12% (6–19%) | 78% (70–87%) | |||||
| ≥30 months | 63% (55–71%) | 19% (13–26%) | 7% (2–11%) | 74% (67–81%) | |||||
| Time interval between the last auto-HCT and salvage auto-HCT | 0.001 | 0.02 | 0.03 | 0.53 | |||||
| <48 months | 41% (33–50%) | 12% (7–18%) | 13% (7–18%) | 75% (68–82%) | |||||
| ≥48 months | 65% (56–74%) | 19% (11–27%) | 4% (0–8%) | 77% (69–85%) | |||||
| Number of previous lines of therapy | 0.42 | 0.49 | 0.22 | 0.30 | |||||
| ≤3 | 48% (38–58%) | 16% (8–23%) | 11% (5–17%) | 73% (64–82%) | |||||
| >3 | 54% (46–62%) | 15% (9–21%) | 7% (3–12%) | 77% (70–84%) | |||||
| Radiotherapy | 0.72 | 0.65 | 0.69 | 0.43 | |||||
| No | 52% (43–62%) | 19% (12–26%) | 10% (5–16%) | 71% (62–79%) | |||||
| Yes | 52% (39–65%) | 14% (5–23%) | 8% (1–15%) | 78% (67–88%) | |||||
| Type of infused stem cells | 0.22 | 0.81 | 0.55 | 0.79 | |||||
| New cells | 61% (49–72%) | 21% (12–30%) | 8% (2–13%) | 71% (61–82%) | |||||
| Mixture | 79% (59–100%) | 18% (0–38%) | 0% (0–0%) | 82% (62–100%) | |||||
| Number of infused CD34+ cells | 0.87 | 0.61 | 0.14 | 0.71 | |||||
| <3 × 106/kg | 53% (43–63%) | 18% (10–26%) | 6% (1–11%) | 75% (67–84%) | |||||
| ≥3 × 106/kg | 58% (48–69%) | 14% (7–21%) | 11% (5–18%) | 75% (66–84%) | |||||
| Plerixafor in remobilization | 0.57 | 0.51 | 0.23 | 0.16 | |||||
| No | 51% (44–58%) | 15% (10–20%) | 10% (6–14%) | 76% (70–82%) | |||||
| Yes | 54% (35–72%) | 25% (9–41%) | 2% (0–6%) | 73% (57–90%) | |||||
| Chemotherapy in remobilization | 0.55 | 0.42 | 0.02 | 0.48 | |||||
| No | 51% (41–60%) | 19% (11–27%) | 5% (1–9%) | 76% (68–84%) | |||||
| Yes | 53% (44–62%) | 13% (7–19%) | 12% (7–18%) | 75% (68–83%) | |||||
| Status of MM at remobilization | 0.11 | 0.30 | 0.82 | 0.94 | |||||
| CR/VGPR/PR* | 52% (44–60%) | 17% (11–23%) | 8% (4–13%) | 75% (68–82%) | |||||
| Other | 42% (24–59%) | 15% (2–27%) | 11% (1–22%) | 74% (59–89%) | |||||
| Durie–Salmon stage at diagnosis | 0.02 | 0.16 | 0.98 | 0.63 | |||||
| I or II | 59% (49–70%) | 18% (10–27%) | 8% (2–14%) | 73% (64–83%) | |||||
| III | 47% (38–56%) | 12% (6–18%) | 9% (4–14%) | 79% (72–86%) | |||||
The 4-year probabilities of OS and PFS were obtained using Kaplan–Meier methods and the 4-year cumulative incidence of NRM and RI was obtained using the crude cumulative incidence estimator. P-values were obtained with the log-rank test for OS and PFS and Gray’s test for NRM and RI and time artificially censored at 6 years.
*VGPR is grouped together with PR and CR vs. Other in order to avoid bias. VGPR has been reported only since 2010.